There is an urgent need for an effective adjuvant systemic therapy for the treatment of @entity1 with advanced @entity135 . This study shows that therapy based on the use of monoclonal antibodies (MAbs) is developing to a realistic option. A few years ago the first MAbs with specificity for @entity957 of the @entity135 ( @entity213 ) were produced, among which was MAb E48. In animal and @entity1 studies, in which localization of radiolabelled MAb E48 was analysed qualitatively and quantitatively, it was demonstrated that a high percentage of the injected dose accumulated selectively in the @entity5 . These targeting properties, when exploited for delivery of toxic agents to the @entity5 , give MAb E48 potential for @entity5 therapy. Especially the application of MAb E48 in radioimmunotherapy (RIT) seems to be attractive due to the intrinsic radiosensitivity of @entity213 . Armed with 186- @entity45619 , a radionuclide recently introduced in the field of RIT, MAb E48 IgG was shown to be highly capable of eradicating established @entity5 in @entity19 . Complete ablation of small @entity213 was observed in this animal model by a single bolus injection. In an effort to make MAb E48 less antigenic for @entity1 application a chimeric @entity1 / @entity19 MAb (cMAb) has been constructed by use of recombinant DNA techniques. This modification strongly improved the capacity of MAb E48 for mediating @entity137 ( @entity137 ). When using this cMAb E48 for RIT of minimal @entity66 it can be anticipated that @entity137 activity may be supportive to irradiation, especially in the ablation of single disseminated cells or small cell aggregates. Extrapolating results obtained in @entity19 to @entity1 and taking into account the good targeting in @entity1 , RIT with E48 IgG seems to have potential for the elimination of minimal @entity66 . Based on this encouraging progress, preparations are being made to evaluate the efficacy of Re-186-labelled cMAb E48 as an adjuvant in a phase III study for the treatment of @entity1 who are at high risk for developing distant metastases.

Progress in radioimmunotherapy of XXXX (review).

@entity1 :: ('9606', 'Species') :: ['patients', 'human', 'patient'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck', 'head and neck cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['ADCC', 'antibody-dependent cellular cytotoxicity'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['HNSCC tumours', 'tumour'] @entity19 :: ('10090', 'Species') :: ['mouse', 'nude mice'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma'] @entity45619 :: ('MESH:D012211', 'Chemical') :: ['Rhenium'] @entity213 :: ('MESH:C535575', 'Disease') :: ['HNSCC']
@entity135 :: (MESH:D006258,Disease) :: ['head and neck-cancer']
